DVAX - NASDAQ

Dynavax Technologies Corporation

DVAX·NASDAQ

$15.50

+0.0000%

HealthcareDrug Manufacturers - Specialty & Generic

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.82B

EPS0.2100

P/E Ratio60.81

Earnings Date05/04/2026

dvax

Inventory

Last Annual Value

70.05M

3-Year CAGR

5-Year CAGR

11%

10-Year CAGR

32%

Adjust for Inflation

Dynavax Technologies Corporation Competitors Analysis of Inventory

DVAX · NASDAQ

Company	Inventory	CAGR 3Y	CAGR 5Y	CAGR 10Y
Dynavax Technologies Corporation NASDAQ:DVAX	70.05M	9.5%	2.7%	N/A
Enliven Therapeutics, Inc. NASDAQ:ELVN	0.00	N/A	N/A	N/A
STAAR Surgical Company NASDAQ:STAA	55.50M	16.5%	26.3%	14.1%
Pacira BioSciences, Inc. NASDAQ:PCRX	152.86M	13.6%	9.2%	17.2%
Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH	176.89M	18.7%	13.8%	8.3%
Beta Bionics, Inc. NASDAQ:BBNX	21.72M	159.4%	N/A	N/A
Pulse Biosciences, Inc. NASDAQ:PLSE	136.00K	N/A	-52.8%	N/A
Collegium Pharmaceutical, Inc. NASDAQ:COLL	40.91M	8.2%	18.7%	41.0%
Harrow Health, Inc. NASDAQ:HROW	13.52M	7.6%	26.2%	22.1%

Dynavax Technologies Corporation Fair Value Envelope

DVAX · NASDAQ

Our analysis suggests that DVAX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.5, this represents a potential HIDDEN relative to our calculated worth for Dynavax Technologies Corporation.

HIDDEN

Intrinsic Value

Current Price: $15.5

Related Guides

Blog Categories

Continue your DVAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.